Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Riches

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Oncotargets and Therapy|March 13, 2024
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic LeukemiaManabu Hayama, John C Riches
Current Cancer Drug Targets|April 9, 2016
Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic LeukemiaJohn C Riches, John G Gribben
Discovery Medicine|December 17, 2013
Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemiaJohn C Riches, John G Gribben
Seminars in Hematology|July 23, 2014
Immunomodulation and immune reconstitution in chronic lymphocytic leukemiaJohn C Riches, John G Gribben
Blood|February 1, 2014
Hanging tough: CMV-specific CD8+ T cells in CLLJohn C Riches, John G Gribben
Hematology. American Society of Hematology. Education Program|December 10, 2013
Immunotherapeutic strategies including transplantation: eradication of diseaseJohn G Gribben, John C Riches
Cancers|May 13, 2023
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future PerspectivesToby A Eyre, John C Riches
Hematology/Oncology Clinics of North America|April 9, 2013
Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implicationsJohn C Riches, John G Gribben
Oncotargets and Therapy|April 6, 2026
Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and ImmunomodulationMeghana K Rajendraprasad, John C Riches
Cancers|December 10, 2021
The Impact of the COVID-19 Pandemic on Oncology Care and Clinical TrialsJennyfa K Ali, John C Riches
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Oncotargets and Therapy|March 13, 2024
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic LeukemiaManabu Hayama, John C Riches
Current Cancer Drug Targets|April 9, 2016
Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic LeukemiaJohn C Riches, John G Gribben
Discovery Medicine|December 17, 2013
Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemiaJohn C Riches, John G Gribben
Seminars in Hematology|July 23, 2014
Immunomodulation and immune reconstitution in chronic lymphocytic leukemiaJohn C Riches, John G Gribben
Blood|February 1, 2014
Hanging tough: CMV-specific CD8+ T cells in CLLJohn C Riches, John G Gribben
Hematology. American Society of Hematology. Education Program|December 10, 2013
Immunotherapeutic strategies including transplantation: eradication of diseaseJohn G Gribben, John C Riches
Cancers|May 13, 2023
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future PerspectivesToby A Eyre, John C Riches
Hematology/Oncology Clinics of North America|April 9, 2013
Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implicationsJohn C Riches, John G Gribben
Oncotargets and Therapy|April 6, 2026
Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and ImmunomodulationMeghana K Rajendraprasad, John C Riches
Cancers|December 10, 2021
The Impact of the COVID-19 Pandemic on Oncology Care and Clinical TrialsJennyfa K Ali, John C Riches
Pageof 3